There are 49 compatible spacers
The use of each medicine included in Right Breathe has been considered in relation to international, national, and regional prescribing pathways. The pathway points at which this medicine is considered a viable prescribing option are included below. If you wish to view the entire pathway, click on its heading, from where you can also access all the prescribing options for each pathway and each pathway point.
Detailed prescribing information is provided below. This content has not been generated by the RightBreathe team, but has been integrated from a 3rd party solution: Multilex (provided by FirstDataBank). Use of this prescribing content is subject to the FirstDataBank disclaimer, which is set out in the "About" section of RightBreathe.
As RightBreathe is a bespoke decision support tool, it covers each and every individual known inhaler option on the UK market to a high level of specificity. Multilex, as a more general resource, does not offer the same level of specificity. There are therefore a small number of medicines for which there are discrepancies between RightBreathe and Multilex content, most notably in relation to licensed particulars and associated licensed doses.
Given the high level of specificity the RightBreathe team work to, details of the individual inhaler licence are most likely to be summarised accurately in the content provided at the top of this page, rather than in the Multilex content below. Where there is ambiguity, users may also wish to refer to individual summaries of product characteristics prior to prescribing.
Type | Age Range | Dose | Licensed |
---|---|---|---|
Single | From 1 month | 1 actuation - ONCE ONLY - inhalation - using a metered dose device | |
Maintenance | From 1 month | 1 to 2 actuations - FOUR times a DAY - PRN - inhalation - using a metered dose device | |
Maintenance | From 1 month | 1 to 2 actuations - when required - inhalation - using a metered dose device - Maximum dose FOUR times a DAY | |
Single | From 1 month | 2 actuations - ONCE ONLY - inhalation - using a metered dose device |
Type | Age Range | Dose | Licensed |
---|---|---|---|
Maintenance | From 1 month to 18 years | 1 to 2 actuations - when required - 10 to 15 minutes before exertion - inhalation - using a metered dose device - Maximum dose FOUR times a DAY | |
Maintenance | From 18 years | 2 actuations - when required - 10 to 15 minutes before exertion - inhalation - using a metered dose device - Maximum dose FOUR times a DAY |
Type | Age Range | Dose | Licensed |
---|---|---|---|
Maintenance | From 1 month | 2 to 10 actuations - every 10 to 20 minutes - PRN - via large volume spacer - inhalation - using a metered dose device |
Type | Age Range | Dose | Licensed |
---|---|---|---|
Maintenance | From 1 month to 18 years | 1 to 2 actuations - when required - 10 to 15 minutes before foreseeable allergen exposure - inhalation - using a metered dose device - Maximum dose FOUR times a DAY | |
Maintenance | From 18 years | 2 actuations - when required - 10 to 15 minutes before foreseeable allergen exposure - inhalation - using a metered dose device - Maximum dose FOUR times a DAY |
With | Risk | Severity |
---|---|---|
(LEVACETYLMETHADOL) | Hypokalaemia with high dose beta-agonist increases risk of arrhythmias | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
ATOMOXETINE | May increase risk of cardiac effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
DOMPERIDONE | Predisposing factors may increase risk of arrhythmias | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
METHACHOLINE | Methacholine effect reduced; review dosing, see product literature | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
SOTALOL | Effect antagonised/ predisposing factors increase risk of arrhythmias | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
(ASTEMIZOLE) | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
(HALOFANTRINE) | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
(RETIGABINE) | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
(SODIUM STIBOGLUCONATE) | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
AJMALINE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
AMIFAMPRIDINE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
AMIODARONE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ANAGRELIDE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ARSENIC TRIOXIDE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ARTEMETHER AND LUMEFANTRINE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
AVAPRITINIB | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
AZITHROMYCIN | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CHLOROQUINE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CILOSTAZOL | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CIPROFLOXACIN | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CITALOPRAM / ESCITALOPRAM | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CLARITHROMYCIN | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
COCAINE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
DELAMANID | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
DISOPYRAMIDE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
DONEPEZIL | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
DRONEDARONE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
DROPERIDOL | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ENTRECTINIB | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ERYTHROMYCIN | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ETELCALCETIDE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
FLECAINIDE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
FLUCONAZOLE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
GLASDEGIB | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
HALOPERIDOL | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
HYDROXYCHLOROQUINE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
HYDROXYZINE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
IBUTILIDE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
INOTUZUMAB | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
IVOSIDENIB | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
LEVOFLOXACIN | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
MELPERONE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
METHADONE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
MOBOCERTINIB | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
MOXIFLOXACIN | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ONDANSETRON | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
OSILODROSTAT | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
OSIMERTINIB | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
OXALIPLATIN | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
PAPAVERINE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
PENTAMIDINE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
PHENOTHIAZINES (QT 1) | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
PIMOZIDE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
PIPERAQUINE AND ARTENIMOL | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
PRALSETINIB | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
PROPOFOL | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
QUINIDINE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
SELPERCATINIB | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
SERTINDOLE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
SEVOFLURANE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
SULPIRIDE | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
TERLIPRESSIN | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
VANDETANIB | Predisposing factors may increase risk of arrhythmias | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ACE INHIBITORS WITH THIAZIDE DIURETICS | Increased risk of hypokalaemia with high doses of beta agonist | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
ACETAZOLAMIDE | Increased risk of hypokalaemia with high doses of beta agonist | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
ANGIOTENSIN II INHIBITORS AND THIAZIDE DIURETICS | Increased risk of hypokalaemia with high doses of beta agonist | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
BETA BLOCKER EYE DROPS | May antagonise effect of each other | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
BETA BLOCKERS | May antagonise effect of each other | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
BETA BLOCKERS AND THIAZIDE DIURETICS | May antagonise effect of each other | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
LOOP DIURETICS | Increased risk of hypokalaemia with high doses of beta agonist | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
THEOPHYLLINE | Increased risk of hypokalaemia with high doses of beta agonist | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
THIAZIDE DIURETICS | Increased risk of hypokalaemia with high doses of beta agonist | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |